Memorial Sloan Kettering Cancer Center

Test

Today is International Translation Day and we're celebrating the Language Services Team at Memorial Sloan Kettering Cancer Center (MSK), a talented group of interpreters committed to making sure MSK patients receive compassionate and culturally appropriate care in their preferred language. Covering 10 of the most common languages and 800+ patient appointments per day, our interpreters bridge communication gaps with empathy and precision, playing a key role in enhancing patient care. The Bilingual Competency Program (BCP), launched by the MSK Language Services Team last year, is an initiative that provides MSK staff the opportunity to learn a new language. To date, the BCP has over 800 members covering 65 languages. This effort complements MSK's commitment to inclusivity to patients by providing language-concordant care and helping overcome linguistic barriers. Thank you, MSK interpreters, for sharing your expertise so that we can best care for all of our patients.

This Advanced Practice Providers (APPs) Week, we are taking the time to celebrate the incredible work of the amazing APPs at Memorial Sloan Kettering Cancer Center (MSK). Every day, they demonstrate dedication, compassion, and expertise, help make a difference in the lives of our patients, and elevate the standard of MSK's oncology care. Their commitment to excellence is truly inspiring - thank you!

Join Dr. Hamza Hashmi and Dr. Carlyn Rose Tan, myeloma specialists at Memorial Sloan Kettering Cancer Center (MSK), today at the 2024 International Myeloma Society's Annual Meeting for their poster session on the “Impact of Daratumumab Refractoriness on Clinical Outcomes Following CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma."

Join Dr. Kylee Maclachlan, a myeloma specialist at Memorial Sloan Kettering Cancer Center (MSK), today at the 2024 International Myeloma Society's Annual Meeting for her plenary discussion, “Para-Medullary (PMD) & Extra-Medullary (EMD) Myeloma Demonstrate Increased Copy Number Aberration, Mutational Burden, Structural Variants, & Genomic Complexity Compared to Marrow-Based Myeloma."

Join Dr. Saad Usmani, a myeloma specialist at Memorial Sloan Kettering Cancer Center (MSK) today at the 2024 International Myeloma Society’s Annual Meeting as he discusses the results from a study on daratumumab + bortezomib/lenalidomide/dexamethasone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma.

Among the most exciting advances in immunotherapy today are vaccines that can treat cancer. These vaccines, known as therapeutic vaccines, empower the patient's own immune system to spot the unique genetic signature of their cancer. The Olayan Center for Cancer Vaccines at Memorial Sloan Kettering (MSK) brings together our world-renowned researchers and clinicians to lead the field in developing cancer vaccines that target a wide range of cancers, including pancreatic and bladder cancer, and metastatic melanoma. Learn more: https://bit.ly/47WAgwh

This World Cancer Research Day, we’re highlighting the importance of cancer research and its role in improving cancer prevention, diagnosis, and treatment. According to the American Association for Cancer Research (AACR), despite exponentially increased investment in oncology research and development, patient participation in oncology clinical trials remains at less than 5% globally. In order to create movement in clinical trials, it’s important for experts from around the world to collaborate to decrease access barriers and leverage leapfrog technologies to increase participation. Memorial Sloan Kettering Cancer Center (MSK), along with Bloomberg New Economy International Cancer Coalition, McKinsey Cancer Center, and Cure4Cancer, helped share this message through a manuscript on Global Health Equity that was commissioned by AACR Cancer Discovery. The multi-stakeholder international cancer coalition envisions a sustainable global ‘hub-and-spoke’ model to advance global health equity in clinical trials access through technology and collaboration, to provide earlier access to innovative medicines and breakthroughs, reduce cost and accelerate the research and development timeline to a 2-3 year process worldwide. Read the manuscript here: https://bit.ly/4elfx7K

For the sixth consecutive year, Memorial Sloan Kettering Cancer Center (MSK) proudly sponsored the African American Day Parade, a celebration of the African American community’s cultural heritage and contributions. Thank you our MSK employees, their families, and friends who joined MSK’s parade float and helped us share our culture of care and inclusivity with the community. Here are some photos from the event.

A new microscope is offering scientists at Memorial Sloan Kettering Cancer Center (MSK) an atom's eye view of the universe inside our cells. Employing a technique called cryogenic electron microscopy — or cryo-EM, for short — MSK’s new fourth-generation Krios microscope fires electrons at two-thirds the speed of light toward samples that have been flash frozen at -180 C (-292 F). Cabinets full of high-powered computer graphics cards process the resulting data, producing 3D movies and frame-by-frame stills that capture fundamental biological machinery in action. With cryo-EM, MSK scientists can observe the most minute processes central to health and development. “MSK’s cryo-EM facility is poised to grow our longstanding history of discovery and leadership in structural biology,” says Dr. Stephen Long, a structural biologist and a member of MSK's Sloan Kettering Institute. "These insights can be expected to lead to a deeper understanding of biological processes that go awry and can cause cancer.” Learn more about how MSK is leading the way with cryo-EM: https://bit.ly/4eAanEj